Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer

Clinical Cancer Research

Volumn 21, Issue 6, 2015, Pages 1383-1394

  Bäumer, Sebastian ^a   Bäumer, Nicole ^a   Appel, Neele ^a   Terheyden, Lisa ^a   Fremerey, Julia ^a   Schelhaas, Sonja ^a   Wardelmann, Eva ^b   Buchholz, Frank ^c   Berdel, Wolfgang E ^a   Müller Tidow, Carsten ^a,d  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; EGFR PROTEIN, MOUSE; KRAS2 PROTEIN, MOUSE; MONOCLONAL ANTIBODY; PROTAMINE; PROTEIN P21;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CELL PROLIFERATION; CELL VIABILITY; CLONOGENESIS; COLON CANCER; COLONY FORMATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SPECIFICITY; DRUG STABILITY; DRUG STRUCTURE; DRUG TARGETING; FEMALE; GENE EXPRESSION REGULATION; IN VITRO STUDY; IN VIVO STUDY; INTERACTIONS WITH RNA; INTERNALIZATION; MONOTHERAPY; MOUSE; NONHUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; TUMOR XENOGRAFT; ADENOCARCINOMA; ANIMAL; ANTAGONISTS AND INHIBITORS; COLONIC NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETICS; HCT116 CELL LINE; HT 29 CELL LINE; HUMAN; IMMUNOLOGY; NUDE MOUSE; RNA INTERFERENCE; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CETUXIMAB; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HT29 CELLS; HUMANS; MICE; MICE, NUDE; PROTAMINES; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84927615838     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2017     Document Type: Article

References (53)

1. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science 2013;339:1546-58.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
3. Smith CG, Fisher D, Claes B,Maughan TS, Idziaszczyk S, Peuteman G, et al. Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy +/- cetuximab. Clin Cancer Res 2013;19:4104-13.
4. Brand TM, Wheeler DL. KRAS mutant colorectal tumors: past and present. Small GTPases 2012;3:34-9.
5. Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, et al. First-inman clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 2011;29:4688-95.
6. Hatzivassiliou G, Haling JR, Chen H, Song K, Price S, Heald R, et al. Mechanism of MEK inhibition determines efficacy in mutant KRAS-versus BRAF-driven cancers. Nature 2013;501:232-6.
7. Lamba S, Russo M, Sun C, Lazzari L, Cancelliere C, Grernrum W, et al. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells. Cell Rep 2014;8:1475-83.
8. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in caenorhabditis elegans. Nature 1998;391:806-11.
9. Tabernero J, Shapiro GI, LoRusso PM, Cervantes A, Schwartz GK, Weiss GJ, et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov 2013;3:406-17.
10. Kaiser PK, Symons RC, Shah SM, Quinlan EJ, Tabandeh H, Do DV, et al. RNAi-based treatment for neovascular age-related macular degeneration by sirna-027. Am J Ophthalmol 2010;150:33-39.e2.
11. Christie RJ, Matsumoto Y, Miyata K, Nomoto T, Fukushima S, Osada K, et al. Targeted polymeric micelles for siRNA treatment of experimental cancer by intravenous injection. ACS Nano 2012;6:5174-89.
12. Hauser PV, Pippin JW, Kaiser C, Krofft RD, Brinkkoetter PT, Hudkins KL, et al. Novel siRNA delivery system to target podocytes in vivo. PLoS ONE 2010;5:e9463.
13. Choi YS, Lee JY, Suh JS, Kwon YM, Lee SJ, Chung JK, et al. The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine. Biomaterials 2009;31:1429-43.
14. Kumar P, Ban HS, Kim SS,WuH, Pearson T,Greiner DL, et al. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 2008;134:577-86.
15. Scott AM, Allison JP, Wolchok JD. Monoclonal antibodies in cancer therapy. Cancer Immun 2012;12:14.
16. Casi G, Neri D. Antibody-drug conjugates: basic concepts, examples and future perspectives. J Control Release 2012;161:422-8.
17. Singer H, Kellner C, Lanig H, Aigner M, Stockmeyer B, Oduncu F, et al. Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16. J Immunother 2010;33:599-608.
18. Kies MS, Harari PM. Cetuximab (imclone/merck/bristol-myers squibb). Curr Opin Investig Drugs 2002;3:1092-100.
19. De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 2011;12: 594-603.
20. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012;486:532-6.
21. Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011;22:1535-46.
22. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.
23. Scholl C, Frohling S, Dunn IF, Schinzel AC, Barbie DA, Kim SY, et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009;137:821-34.
24. Dunn EF, Iida M, Myers RA, Campbell DA, Hintz KA, Armstrong EA, et al. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab. Oncogene 2011;30:561-74.
25. Okudela K, Hayashi H, Ito T, Yazawa T, Suzuki T, Nakane Y, et al. K-ras gene mutation enhances motility of immortalized airway cells and lung adenocarcinoma cells via akt activation: possible contribution to non-invasive expansion of lung adenocarcinoma. Am J Pathol 2004; 164:91-100.
26. Ji P, Agrawal S, Diederichs S, BaumerN, Becker A, Cauvet T, et al. Cyclin A1, the alternative A-type cyclin, contributes to G1/S cell cycle progression in somatic cells. Oncogene 2005;24:2739-44.
27. Schmidt LH, Spieker T, Koschmieder S, Schaffers S, Humberg J, Jungen D, et al. The long noncoding MALAT-1RNAindicates a poor prognosis in nonsmall cell lung cancer and induces migration and tumor growth. J Thorac Oncol 2011;6:1984-92.
28. Hansen B, Linde S, Kolendorf K, Jensen F. Absorption of protamine-insulin in diabetic patients. I. preparation and characterization of protamine-125I-insulin. Horm Metab Res 1979;11:85-90.
29. Sunada H, Magun BE, Mendelsohn J, MacLeod CL. Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc Natl Acad Sci U S A 1986;83:3825-9.
30. Surendranath V, Theis M, Habermann BH, Buchholz F. Designing efficient and speci fic endoribonuclease-prepared siRNAs. Methods Mol Biol 2013;942:193-204.
31. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple rasdependent phosphorylation pathways regulate myc protein stability. Genes Dev 2000;14:2501-14.
32. Chase A, Cross NC. Aberrations of EZH2 in cancer. Clin Cancer Res 2011;17:2613-8.
33. Hirabayashi N, Noso Y, Niimi K, Nishiyama M, Yamaguchi M, Toge T, et al. Comparative studies on in vitro human tumor clonogenic assay (HTCA) and in vivo nude mouse-isotope assay (NM-IA). Jpn J Surg 1987;17:104-9.
34. AhmedD, Eide PW, Eilertsen IA,Danielsen SA, Eknaes M, HektoenM, et al. Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis 2013;2:e71.
35. Jhawer M, Goel S, Wilson AJ, Montagna C, Ling YH, Byun DS, et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 2008;68:1953-61.
36. Chong CR, Janne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med 2013;19:1389-400.
37. Janne PA, Shaw AT, Pereira JR, Jeannin G, Vansteenkiste J, Barrios C, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 2013;14:38-47.
38. Troiani T,Napolitano S, VitaglianoD, Morgillo F, Capasso A, Sforza V, et al. Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERKpathway activation and can be overcome by combined MEK/EGFR inhibition. Clin Cancer Res 2014;20:3775-86.
39. Wang X, Cunningham M, Zhang X, Tokarz S, Laraway B, Troxell M, et al. Phosphorylation regulates c-myc's oncogenic activity in the mammary gland. Cancer Res 2011;71:925-36.
40. Coppola JA, Cole MD. Constitutive c-myc oncogene expression blocks mouse erythroleukaemia cell differentiation but not commitment. Nature 1986;320:760-3.
41. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357: 2040-8.
42. Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identi fies HER2 as an effective therapeutic target in cetuximabresistant colorectal cancer. Cancer Discov 2011;1:508-23.
43. Verma UN, Surabhi RM, Schmaltieg A, Becerra C, Gaynor RB. Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res 2003;9:1291-300.
44. Judge A, MacLachlan I. Overcoming the innate immune response to small interfering RNA. Hum Gene Ther 2008;19:111-24.
45. Bulk E, Sargin B, Krug U, Hascher A, Jun Y, Knop M, et al. S100A2 induces metastasis in non-small cell lung cancer. Clin Cancer Res 2009;15:22-9.
46. Bulk E, Hascher A, Liersch R, Mesters RM, Diederichs S, Sargin B, et al. Adjuvant therapy with small hairpin RNA interference prevents non-small cell lung cancer metastasis development in mice. Cancer Res 2008;68: 1896-904.
47. Zorde Khvalevsky E, Gabai R, Rachmut IH, Horwitz E, Brunschwig Z, Orbach A, et al. Mutant KRAS is a druggable target for pancreatic cancer. Proc Natl Acad Sci U S A 2013;110:20723-8.
48. Petrocca F, Lieberman J. Promise and challenge of RNA interference-based therapy for cancer. J Clin Oncol 2010;29:747-54.
49. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002;2:750-63.
50. Castaigne S, Pautas C, Terre C, Raffoux E, Bordessoule D, Bastie JN, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with denovo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012;379:1508-16.
51. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783-91.
52. Lambert JM. Drug-conjugated antibodies for the treatment of cancer. Br J Clin Pharmacol 2013;76:248-62.
53. Shimizu N, Chen J, Gamou S, Takayanagi A. Immunogene approach toward cancer therapy using erythrocyte growth factor receptor-mediated gene delivery. Cancer Gene Ther 1996;3:113-20.